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Abstract
Background: Ventriculitis is a complication of temporary intraventricular drains. The limited penetration of
meropenem into the cerebrospinal fluid (CSF) is well known. However, ventricular CSF pharmacokinetic data in
patients with ventriculitis are lacking. The aim of this study was to evaluate meropenem pharmacokinetics in the
serum and CSF of neurocritical care patients with proven or suspected ventriculitis.
Methods: We conducted an observational pharmacokinetic study of neurocritical care patients with proven or
suspected ventriculitis receiving meropenem. Multiple blood and CSF samples were taken and were described
using nonparametric pharmacokinetic modelling with Pmetrics.
Results: In total, 21 patients (median age 52 years, median weight 76 kg) were included. The median (range) of
peak and trough concentrations in serum were 20.16 (4.40–69.00) mg/L and 2.54 (0.00–31.40) mg/L, respectively.
The corresponding peak and trough concentrations in CSF were 1.20 (0.00–6.20) mg/L and 1.28 (0.00–4.10) mg/L,
respectively, with a median CSF/serum ratio (range) of 0.09 (0.03–0.16). Median creatinine clearance ranged from 60.
7 to 217.6 ml/minute (median 122.5 ml/minute). A three-compartment linear population pharmacokinetic model
was most appropriate. No covariate relationships could be supported for any of the model parameters. Meropenem
demonstrated poor penetration into CSF, with a median CSF/serum ratio of 9 % and high interindividual
pharmacokinetic variability.
Conclusions: Administration of higher-than-standard doses of meropenem and therapeutic drug monitoring in
both serum and CSF should be considered to individualise meropenem dosing in neurocritical care patients with
ventriculitis.
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Background
Neurocritical care patients often require implantation of
an intraventricular catheter (IVC) to manage hydroceph-
alus and monitor intracranial pressure [1, 2]. IVC-related
ventriculitis and/or meningitis are the primary complica-
tions in these patients [3]. Infection rates are approxi-
mately 10 %, and they are associated with significant
morbidity and mortality [1, 3]. Meropenem plus vanco-
mycin is a frequently used antimicrobial combination for
management of IVC-related infections because of its
broad spectrum of antimicrobial activity [2, 4]. Neverthe-
less, relatively little is known about the pharmacokinetics
(PK) of meropenem in the cerebrospinal fluid (CSF) of pa-
tients with ventriculitis [5, 6].
Meropenem exhibits time-dependent antimicrobial ac-
tivity [7]. Its antibacterial effect is related primarily to the
fraction of the dosing interval that the unbound concen-
tration is above the minimum inhibitory concentration
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(fT>MIC) [7]. The bactericidal activity of meropenem in la-
boratory animal models requires 40–50 % fT>MIC in plasma
[8, 9]. The relevance of this estimate for infections within
the central nervous system (CNS) is not known. A signifi-
cant challenge for critical care physicians is achieving and
maintaining appropriate concentrations at the target site of
infection (i.e., the CSF for neurocritical care patients). In
randomised clinical trials, meropenem was as effective as
cefotaxime and ceftriaxone for treating community-
acquired bacterial meningitis in children and adults [10,
11]. The penetration of antibiotics into the CNS is de-
pendent on several factors, such as the presence of menin-
geal inflammation [5, 6]. The meninges in ventriculitis are
typically normal or only minimally inflamed [5, 6]. Thus,
penetration into the CNS in patients with ventriculitis
should not be extrapolated from other patient populations.
While meropenem is recommended for the empirical treat-
ment of meningitis and IVC-related infections [2, 4], there
are no comparative efficacy trials for patients with minim-
ally inflamed meninges with ventriculitis and no clear idea
of optimal regimens for this patient group.
The aim of this study was to evaluate meropenem con-
centrations in the serum and CSF of neurocritical care
patients with IVC and proven or suspected ventriculitis.
This study provides a first critical step in identifying reg-
imens of meropenem that can be used to treat patients
with ventriculitis. These regimens can then be further
studied in clinical trials and are a way in which clinical
outcomes can potentially be improved.
Methods
Study design and population
This prospective, observational PK study was performed at
the intensive care unit (ICU) of Munich University Hospital,
Munich, Germany, between April 2014 and January 2016.
The trial was conducted in accordance with the Declaration
of Helsinki. Ethical approval was obtained from the univer-
sity ethics committee (registration number 111-14). Written
informed consent was obtained from all patients or their le-
gally authorised representatives before enrolment. Patients
were enrolled in the study if they were admitted to the ICU
having an IVC and proven or suspected ventriculitis.
Proven ventriculitis was defined as a positive CSF culture
combined with clinical signs of infection [12]. Suspected
ventriculitis was defined by abnormal CSF parameters, such
as low CSF glucose levels (<50 % of serum glucose), high
CSF protein (>50 mg/dl) or CSF pleocytosis, combined with
clinical signs of infection and in the absence of a positive
CSF culture [12]. Patients were excluded if they were under
18 years of age or death within 72 h was predicted.
Drug administration
Meropenem (Meropenem Hikma®; Hikma Pharma,
Gräfelfing, Germany) was administered as a prolonged
infusion over 4 h using a syringe pump. The dose was
2000 mg every 8 h for all patients, except for those with
adverse drug effects or renal impairment (creatinine
clearance [CrCL] ≤50 ml/minute), for whom the dose
was reduced to 1000 mg every 8 h at the discretion of
the attending physician.
Study procedures
Serial blood and CSF sampling occurred for initial dose
and steady state (daily on days 1–3, followed by every
second or third day). Blood samples (4 ml) were col-
lected using the indwelling arterial catheter just before
the start of the infusion (serum trough concentration
[Cmin]) and after the end of the infusion (serum peak
concentration [Cmax]). CSF samples (1 ml) were collected
using the indwelling IVC nearest to the site of insertion
(3-ml volume to sampling location) simultaneously with
each blood sample just before the start of the infusion
(cerebrospinal fluid concentration at serum trough con-
centration [Ctrough]) and after the end of the infusion
(cerebrospinal fluid concentration 4 h after serum trough
concentration [Cafter 4h]). Samples were centrifuged for
5 minutes at 4000 rpm immediately after sample collec-
tion and aliquoted into 2-ml propylene tubes (Eppendorf,
Hamburg, Germany). Aliquots were stored at −80 °C
within 45 minutes after sample collection for a maximum
of 4 weeks until assay. Additional data were obtained from
the medical record, including weight, height, serum cre-
atinine, bilirubin, serum C-reactive protein (CRP), serum
interleukin-6 (IL-6), serum procalcitonin (PCT), serum
leucocytes, CSF cells, CSF erythrocytes, CSF IL-6, CSF
glucose, CSF protein, CSF drain in 24 h, Simplified Acute
Physiology Score II (SAPS II), Sepsis-related Organ Failure
Assessment (SOFA) score, Glasgow Coma Scale (GCS)
and dexamethasone therapy.
Bioanalytical methodology
Serum and CSF concentrations of meropenem were ana-
lysed using a validated high-performance liquid chroma-
tography assay with ultraviolet detection. The analyses
were performed in the laboratory of the pharmacy depart-
ment of Heidenheim General Hospital [13]. The assay was
linear from 1 to 30 mg/L in serum and from 0.5 to 5 mg/L
in CSF with a relative SD for intra- and interday precision
and accuracy <5 % at high, medium and low concentra-
tions. The limits of quantification were 0.5 mg/L for
serum samples and 0.2 mg/L for CSF samples.
Population pharmacokinetic analysis
The oncentration–time data for meropenem in serum
and CSF were analysed using a non-parametric popula-
tion methodology with the nonparametric adaptive grid
program Pmetrics version 1.3.2 [14]. The structure of
the PK mathematical model fitted to the study data was
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modified from a previously published meropenem model
[15] and took the following form:
dX1=dt ¼ RðtÞCL=Vc  X1kcp  X1kbc
 X1þ kpc  X2þ kbc  X3 ð1Þ
dX2=dt ¼ kcp  Xð1Þkpc  X2 ð2Þ
dX3=dt ¼ kcb  Xð1Þkbc  X3 ð3Þ
These three equations describe a three-compartment
pharmacokinetic model with central, peripheral and CSF
compartments denoted by the numbers 1, 2 and 3,
respectively. R(t) in milligrams per hour represents the
zero-order infusion of meropenem. Meropenem was
cleared from the central compartment (clearance in
litres per hour), which also has a volume (Vc; given in
litres). Kcp, Kpc, Kcb and Kbc represent first-order transfer
constants connecting the various compartments. The
CSF compartment (X3) has an apparent CSF volume
(VCSF; given in litres). Equation (1) describes the rate of
change of the amount of meropenem (in milligrams) in the
central compartment (X1). Equation (2) describes the rate
of change of the amount of meropenem (in milligrams) in
the peripheral compartment (X2). Equation (3) describes
the rate of change of the amount of meropenem (in
milligrams) in the CSF compartment (X3).
In Pmetrics, error can be separately attributed to assay
variance and additional process noise such as errors in
sampling time or dosing. The data were weighted using
the inverse of the estimated assay variance. Additional
process noise such as errors in sampling time or dosing
was modelled using a fixed lambda as an additive error
term in Pmetrics.
Population pharmacokinetic model diagnostics
The fit of the PK model to the data set was assessed in
the following ways: (1) the log-likelihood value, (2) the
coefficient of determination (r2) of the linear regression
and (3) visual inspection of diagnostic scatterplots,
where model predictions were generated either by the
median population parameter values or by the medians
of each subject’s individual Bayesian posterior parameter
value distributions.
Population pharmacokinetic covariate screening
The impact of weight, CrCL, bilirubin, serum CRP,
serum IL-6, serum PCT, serum leucocytes, CSF cells,
CSF erythrocytes, CSF IL-6, CSF glucose, CSF protein,
CSF drain in 24 h, SAPS II, SOFA score and GCS as co-
variates was initially assessed by visual inspection. For
that reason, graphical representation in Pmetrics of each
covariate versus population parameter was performed to
evaluate for inclusion in the final model.
Other pharmacokinetic calculations
Cmax and Cmin in serum and Cafter 4 h and Ctrough in CSF
are the observed values. The average AUC for each
patient was calculated using the Bayesian posterior
parametric estimates from the final model using the
trapezoidal rule in Pmetrics. We divided each subject’s
cumulative AUC (AUCf) by the total time in hours and
multiplied the result by 24 to estimate the daily average
AUC (AUC0–24). Penetration of meropenem into CSF
was described using the CSF/serum ratio, which was cal-
culated by dividing the CSF AUCf by the serum AUCf.
Half-life was calculated using transfer rate constants.
CrCL was calculated using the Cockcroft-Gault equation
[16]. All calculations were performed using IBM SPSS
Statistics version 23.0 software (IBM, Armonk, NY, USA).
Assessment of meropenem concentration in CSF
Simulations of 1000 patients were performed using
Pmetrics to compare different dosing regimens in this
study population (2000 mg every 8 h, 4000 mg every 8 h,
Table 1 Patient characteristics
Characteristic Data
Age, years, median (range) 52 (46–80)
Weight, kg, median (range) 76 (55–105)
Body mass index, kg/m2, median (range) 25.95 (20–33)
Sex, male/female 52.4 %/47.6 %
CrCL on day of inclusion, ml/minute,
median (range)
120.1 (52.3–217.6)
CRP in serum on day of inclusion, mg/dl,
median (range)
3.1 (0.4–36.7)
Interleukin-6 in serum on day of inclusion,
pg/ml, median (range)
13.7 (2.4–274.0)
CSF drain in 24 h on day of inclusion,
median (range)
183 (21–360)
Interleukin-6 in CSF on day of inclusion,
pg/ml, median (range)
3398 (140–24,522)
Cells in CSF on day of inclusion, n/μl,
median (range)
503 (4–2894)
Protein in CSF on day of inclusion,
mg/L, median (range)
107 (13–303)
Glucose in CSF on day of inclusion,
mg/dl, median (range)
72 (47–126)
Glucose CSF/serum ratio on day of inclusion,
median (range)
0.55 (0.38–0.99)
SAPS II on day of inclusion 47 (13–62)
SAPS II on day of exclusion, median (range) 32 (13–61)
SOFA score on day of inclusion, median (range) 6 (1–12)
SOFA score on day of exclusion, median (range) 2.5 (0–8)
30-day mortality 0
Abbreviations: CrCL Estimated creatinine clearance (calculated using the
Cockcroft-Gault equation [16]), CRP C-reactive protein, CSF Cerebrospinal fluid,
SOFA Sepsis-related Organ Failure Assessment, SAPS II Simplified Acute
Physiology Score II
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4000 mg every 6 h, 5000 mg every 6 h; 4-h infusion). In
addition, probability of target attainment (PTA) in CSF
was analysed using Pmetrics to achieve meropenem con-
centrations in CSF of 1 mg/L, 2 mg/L and 4 mg/L. Linear
regression was performed using Pmetrics. PTA presenta-
tion was performed using IBM SPSS software.
Results
In total, 209 blood samples and 199 CSF samples from 21
patients were included in the model. The demographic and
general clinical characteristics of patients are shown in
Table 1. Briefly, the study population was relatively young
(median age 52 years, range 46–80 years) and had well-
preserved renal function on the day of inclusion (median
CrCL 120.1 ml/minute, range 52.3–217.6 ml/minute). The
median (range) SAPS II score was 47 (13–62). All patients
received vancomycin therapy in addition to meropenem.
Vancomycin was replaced by linezolid in one patient
(4.8 %), owing to an increase in serum creatinine level.
Seven patients (33.3 %) received concomitant fosfomycin
for 7 days, although one (4.8 %) of them also received ri-
fampicin, which then was replaced by fosfomycin. Patient 1
additionally received dexamethasone during the first 2 days,
and patient 14 additionally received dexamethasone during
the first 5 days. The most frequent neurological disease was
subarachnoid haemorrhage, observed in 17 (81.0 %) pa-
tients. In the remaining four patients, an IVC was placed
for intracranial bleeding (4.8 %), tumour (9.5 %) or trau-
matic brain injury (4.8 %). A total of 20 patients (95.2 %)
were CSF culture-negative, and one patient (4.8 %) had a
positive culture for Pseudomonas aeruginosa that was sus-
ceptible to meropenem.
In serum, the median Cmax (range) was 20.16 (4.40–
69.00) mg/L and the median Cmin (range) was 2.54
Table 2 Observed meropenem concentrations in serum and cerebrospinal fluid
Meropenem dosing 1000 mg Meropenem dosing 2000 mg
Patient number CrCL
(ml/minute)
Cmin
(mg/L)
Cmax
(mg/L)
Ctrough
(mg/L)
Cafter 4h
(mg/L)
Cmin
(mg/L)
Cmax
(mg/L)
Ctrough
(mg/L)
Cafter 4h
(mg/L)
1 60.7 3.80 N/A 2.00 N/A 10.90 48.60 3.00 4.00
2 156.8 6.90 11.00 N/A N/A 4.60 26.35 2.75 2.60
3 83.8 4.80 24.10 2.60 1.90 13.80 45.30 2.25 3.45
4 162.9 N/A N/A N/A N/A 1.10 16.40 0.60 0.60
5 217.6 <0.5 5.80 N/A N/A 2.90 19.40 0.31 0.53
6 124.5 N/A N/A N/A N/A 0.86 19.20 0.76 0.86
7 120.1 N/A N/A N/A N/A <0.5 15.20 0.43 0.78
8 73.1 N/A N/A N/A N/A 11.00 64.80 3.35 3.00
9 92.1 0.81 12.30 1.08 0.97 3.05 19.65 1.40 1.97
10 96.3 N/A N/A N/A N/A 1.31 33.30 1.62 1.04
11 142.9 N/A 12.82 N/A 1.14 1.02 19.33 0.62 0.74
12 174.1 0,62 5.62 0.39 0.32 N/A N/A N/A N/A
13 100.3 1.38 10.65 1.47 1.15 0.79 19.80 0.87 0.80
14 96.2 N/A N/A N/A N/A 9.83 32.94 2.27 2.19
15 108.8 N/A N/A N/A N/A 1.13 17.51 1.18 0.88
16 125.0 N/A N/A N/A N/A 2.99 27.01 0.92 1.17
17 144.7 N/A N/A N/A N/A 2.44 18.15 0.74 0.58
18 90.5 N/A 20.10 N/A 2.28 7.63 33.80 2.39 1.84
19 131.3 2.50 17.47 0.89 0.83 6.22 26.94 1.79 1.82
20 174.6 N/A N/A N/A N/A 2.63 23.23 1.52 1.58
21 122.5 1.69 10.57 <0.2 0.25 3.65 16.74 0.31 0.44
Median 122.5 1.69 11.65 1.08 1.05 2.95 21.51 1.29 1.10
Minimum 60.7 <0.5 4.40 <0.2 <0.2 <0.5 10.70 <0.2 0.24
Maximum 217.6 7.10 26.60 3.10 2.80 31.40 69.00 4.10 6.20
Abbreviations: Cmin Median observed serum trough concentration, Cmax Median observed serum peak concentration, Ctrough Median observed cerebrospinal
fluid concentration at serum trough concentration, Cafter 4h Median observed cerebrospinal fluid concentration 4 h after serum trough concentration, N/A Not
available (patient with only meropenem 1000 mg or only 2000 mg intravenously every 8 h), CrCL Estimated creatinine clearance (calculated using the Cockcroft-
Gault equation [16])
Observed meropenem concentrations after 1000 mg or 2000 mg intravenously every 8 h (4-h infusion)
Blassmann et al. Critical Care  (2016) 20:343 Page 4 of 9
(0.00–31.40) mg/L. In CSF, the median Cafter 4h (range)
was 1.20 (0.00–6.20) mg/L and the median Ctrough
(range) was 1.28 (0.00–4.10) mg/L. The median CrCL
ranged from 60.7 to 217.6 ml/minute (median 122.5 ml/
minute). Individual observed meropenem concentrations
and median CrCL values are shown in Table 2. The me-
dian AUC0–24 in CSF was 26.56 mg∙h/L, and in serum it
was 350.22 mg∙h/L. The values for the AUC0–24 in CSF
and serum ranged from 7.44 to 85.53 mg∙h/L and from
112.95 to 768.63 mg∙h/L, respectively. The median CSF/
serum ratio (range) was 0.09 (0.03–0.16). Individual
AUC0–24 and penetration results are shown in Table 3.
Pharmacokinetic model building
The three-compartment model was adequately able to de-
scribe the observed concentrations for the full data set. The
fit of the population PK model was acceptable according to
visual inspection of the observed-versus-predicted plots
and r2 of the observed-versus-predicted values (r2 = 0.926
in serum, r2 = 0.694 in CSF) (Fig. 1). Individual PK results
in serum and CSF obtained by Pmetrics for the PK model
are shown in Table 3. The mean, median and SD for the
population parameters identified by Pmetrics for the PK
model are shown in Table 4. No covariate relationships
could be supported for any of the model parameters.
Assessment of meropenem concentration in CSF
Simulated meropenem concentration–time profiles in
serum and CSF of each regimen are shown in Fig. 2.
The proportions of simulated patients who exceeded tar-
geted meropenem concentrations in CSF of each regi-
men are shown in Fig. 3.
Discussion
To our knowledge, this is the first population PK study
of meropenem concentrations in serum and CSF in neu-
rocritical care patients with ventriculitis. Furthermore, it
is also the largest study investigating the penetration of
Table 3 Pharmacokinetic properties of meropenem in serum and cerebrospinal fluid
Patient number CL (L/h) Vc (L) t1/2 (h) AUC0–24 serum (mg∙h/L) AUC0–24 CSF (mg∙h/L) CSF/serum ratio t1/2cb (h) t1/2bc (h)
1 7.63 6.45 0.59 768.63 85.53 0.11 3.30 4.62
2 17.88 14.45 0.56 327.09 53.00 0.16 17.33 9.90
3 8.62 14.95 1.20 428.94 48.59 0.11 4.62 3.47
4 20.38 5.05 0.17 300.14 19.37 0.06 13.86 17.33
5 22.87 14.95 0.45 237.60 8.93 0.04 17.33 2.57
6 14.89 5.05 0.24 401.45 18.63 0.05 34.66 69.31
7 23.37 14.95 0.44 258.79 15.02 0.06 34.66 5.78
8 7.88 5.05 0.44 760.20 79.10 0.10 8.66 9.90
9 17.13 14.95 0.60 280.81 26.56 0.09 23.10 17.33
10 11.88 13.75 0.80 489.44 27.25 0.06 69.31 34.66
11 20.63 12.75 0.43 287.15 15.59 0.05 34.66 17.33
12 29.87 9.95 0.23 112.95 10.56 0.09 11.55 9.90
13 15.07 5.05 0.23 234.65 22.10 0.09 23.10 69.31
14 9.63 14.95 1.08 569.59 48.90 0.09 13.86 5.78
15 14.88 5.05 0.24 413.23 25.62 0.06 34.66 69.31
16 17.13 14.95 0.60 337.21 30.99 0.09 23.10 17.33
17 14.98 5.08 0.24 415.22 17.31 0.04 34.66 69.31
18 10.63 5.05 0.33 563.84 42.95 0.08 5.78 8.66
19 13.12 14.95 0.79 394.45 33.99 0.09 34.66 13.86
20 17.13 14.95 0.60 350.22 33.71 0.10 23.10 17.33
21 18.88 14.15 0.52 242.60 7.44 0.03 17.33 1.73
Median 15.07 13.75 0.63 350.22 26.56 0.09 23.10 13.86
Minimum 7.63 5.05 0.17 112.95 7.44 0.03 3.30 1.73
Maximum 29.87 14.95 1.20 768.63 85.53 0.16 69.31 69.31
Abbreviations: CSF Cerebrospinal fluid, CL Median clearance, t1/2 Median half-life, Vc Median volume of distribution of the central compartment, AUC0–24 Daily aver-
age area under the curve, CSF/serum ratio Cerebrospinal fluid penetration, t1/2cb Median absorption half-life into cerebrospinal fluid, t1/2bc Median elimination half-
life of cerebrospinal fluid
Individual pharmacokinetic results in serum and CSF obtained using Pmetrics
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meropenem into CSF. We found that meropenem poorly
penetrated into CSF, with a median penetration ratio of
only 9 %. However, there was considerable interindivid-
ual variability in serum and CSF concentrations and re-
sultant CSF/serum ratios. This variation is most likely
due to the range of sickness severity and the consequent
effect of altered physiology on meropenem exposure, as
well as to the integrity of the blood–CSF barrier. These
findings are concordant with those derived from
previous studies in which researchers have also de-
scribed large interindividual variability in meropenem
concentrations in serum [17] and CSF [18]. However, PK
variability was not explained by any covariates. There-
fore, our study suggests the need for therapeutic drug
monitoring of meropenem in both serum and CSF to
avoid treatment failures due to underexposure or over-
dosing resulting in potential side effects, as suggested by
a case report by Lonsdale et al. [19].
CSF is produced by the choroid plexus [20]. Drug
penetration into CSF is indicative of the transport across
the choroid plexus at the blood–CSF barrier [21]. The
blood–CSF barrier is ‘leaky’ compared with the blood–
brain barrier, and molecules enter the CSF by diffusion
at a rate that is inversely proportional to their molecular
weight [20, 21]. Our PK model suggests that meropenem
penetration (median 23 h) is slower than CSF clearance
(median 14 h). Approximately 24–48 h are required to
achieve steady-state concentrations in the CSF (Fig. 1).
In future studies, researchers could examine innovative
ways to achieve effective CSF concentrations as quickly
as possible. Robust estimates of early penetration would
require optimal sampling in this early treatment period.
Neither accumulation of drug nor significant intraindividual
variability over the treatment course was observed. The
apparently high volume of CSF reflects the relatively low
CSF concentrations compared with serum. VCSF should not
be viewed as the physiological CSF volume; it is merely a
scalar that explains the concentration observed in the CSF.
A CSF penetration of meropenem of 20 % in normal
or mildly infected meninges and 39 % in inflamed men-
inges is described elsewhere [6]. However, studies citing
relatively higher CSF penetration (e.g., 21 % [22], 25 %
[23], 39 % [10]) have been conducted in patients with
bacterial meningitis [10, 23] or with CSF that was col-
lected by lumbar drainage [22]. Nau et al. [18] observed
a CSF penetration of meropenem of 4.6 % (range
1.9–8.9 %) in ten neurocritical care patients with extra-
cerebral infections [18]. This is similar to our findings
Fig. 1 Diagnostic plots for the final population pharmacokinetics
model. Individual predicted meropenem concentrations in serum
versus observed serum concentrations (r2 = 0.926) (a) and individual
predicted meropenem concentrations in cerebrospinal fluid (CSF)
versus observed CSF concentrations (r2 = 0.694) (b), indicating that
92.6 % in serum and 69.4 % in CSF of the observed variability in
meropenem concentrations were explained by the parametric
distributions in the model. The solid black line shows the linear
regression line of fit. The estimates of bias and imprecisions were
also acceptable (−0.172 and 1.47 in serum and −0.0545 and 0.389 in
CSF, respectively)
Table 4 Population pharmacokinetic mean, median and SD
parameters of meropenem obtained using Pmetrics
Mean Median SD
CL, L/h 16.045 15.025 ±5.575
Vc, L 10.949 13.736 ±4.491
Kcp, L
−1 1.562 1.248 ±1.031
Kpc, L
−1 1.686 1.898 ±1.206
Kcb, L
−1 0.052 0.026 ±0.049
Kbc, L
−1 0.092 0.054 ±0.097
VCSF, L 82.932 93.902 ±18.802
Abbreviations: CL Clearance, Vc Volume of distribution of the central
compartment, VCSF Volume of distribution of the cerebrospinal fluid
compartment, Kcp, Kpc, Kbc, Kcb Linear transfer rate constants
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considering high interindividual variability in CSF/serum
ratios. In this study, meropenem clearance in serum
(16.0 L/h) was greater than that reported in other PK
studies in critically ill patients (7.7–9.4 L/h [24], 9.3 L/h
[25], 11.5 L/h [26], 13.6 L/h [27]). However, the patients in
our study were generally young and without any measured
renal dysfunction on the day of inclusion. Interestingly, in
a previous study with healthy volunteers (16.3 L/h [28]),
researchers described similar meropenem clearance. The
fact that the clearance in our patients was similar to that
observed in healthy volunteers may be due to the rela-
tively preserved renal function of our patient population
(median CrCL 122 ml/minute) in contrast to the renal
function in other studies (mean CrCL 84 ml/minute [24],
78 ml/minute [25], 61 ml/minute [26], 100 ml/minute
[27]). Greater than normal CrCL is common in neurocriti-
cal care patients [29], which may lead to sub-therapeutic
concentrations of time-dependent antibiotics such as
β-lactam agents. Augmented renal clearance has previ-
ously been shown to be an independent predictor of not
achieving the pharmacokinetic/pharmacodynamic (PD)
target for meropenem [19, 30, 31] as well as other
β-lactams [30–33]. Nevertheless, patients’ renal function
was not a covariate in our model. CrCL was the most im-
portant predictor for meropenem clearance with impaired
renal function, although no correlation was observed be-
tween CrCL and meropenem clearance above CrCL of
100 ml/minute [31, 34].
The most dreaded pathogens in nosocomial CNS in-
fection are aerobic Gram-negative pathogens (e.g., P.
Fig. 2 Comparison of different dosing regimens as prolonged infusions over 4 h using the pharmacokinetics model. Median time course of
meropenem concentrations simulated in serum and cerebrospinal fluid (CSF) over 4 days. Targeted meropenem trough concentrations in CSF
were 1 mg/L, 2 mg/L and 4 mg/L
Fig. 3 Probability of target attainment in cerebrospinal fluid (CSF)
for different dosing regimens as prolonged infusions over 4 h. The
proportions of simulated patients who exceeded meropenem
trough concentrations in CSF greater than or equal to 1 mg/L,
2 mg/L and 4 mg/L for each regimen are shown
Blassmann et al. Critical Care  (2016) 20:343 Page 7 of 9
aeruginosa), Staphylococcus aureus and Staphylococcus
epidermidis [2, 4]. From a PD point of view, CSF con-
centrations in our study population exceeded minimum
inhibitory concentrations (MICs) for most members of
the Enterobacteriaceae family (<0.125 mg/L), including
Klebsiella pneumoniae and methicillin-sensitive S. aureus
(0.25 mg/L) [9]. However, only 53.8 % of the simulated
patients exceeded CSF trough concentrations of 2 mg/L
with 2000 mg meropenem every 8 h, assuming all drug
in the CSF is unbound (Fig. 3). In contrast, 95.1 % of
simulated patients exceeded CSF trough concentrations
of 2 mg/L with a regimen of 5000 mg meropenem every
6 h (Fig. 3). Therefore, in neurocritical care patients with
CNS infections caused by pathogens with borderline
susceptibility such as P. aeruginosa (2 mg/L) [9], the
standard dosing regimen of meropenem 2000 mg every
8 h as a prolonged infusion is unlikely to achieve ad-
equate CSF concentrations. More work is required to
better understand PD targets at the site of infection for
patients with ventriculitis.
There are several limitations of this study. First, the
study was relatively small, which may have hampered
robust estimates of the extent of PK variability and
the identification of covariates that may have ex-
plained some of the observed variance. CrCL was es-
timated because the measurement is not routinely
performed in routine clinical care. Second, we measured
total drug concentrations because protein binding is not
relevant for low to moderately protein-bound drugs
(unbound fraction 91–98 %) [9]. Finally, all but one
patient had suspected ventriculitis without a positive
CSF culture. Therefore, we were unable to establish
PK–PD relationships. Such an analysis would have
been helpful to help establish drug exposure targets
at the site of infection.
Conclusions
To our knowledge, this is the largest PK study of neuro-
critical care patients with proven or suspected ventriculi-
tis. We found that meropenem showed relatively low
penetration into CSF. Furthermore, high interindividual
variability in serum and CSF concentrations was ob-
served. Assuming MIC serum breakpoints, adequate
CSF concentrations are not assured for pathogens with
borderline susceptibility such as P. aeruginosa. To ad-
dress this challenge, novel dosing strategies should be
investigated in further clinical studies with high daily
dosages and/or with administration by continuous infu-
sion to avoid antibiotic underexposure in the context of
augmented elimination or impaired target side penetra-
tion. The safety of these higher-dose regimens must be
established. An alternative approach to optimising mero-
penem exposure is to use individualised dosing to achieve
the desired drug exposure in both serum and CSF.
Key message
 Currently recommended regimens for meropenem
for proven or suspected ventriculitis may lead to
insufficient drug concentrations in cerebrospinal
fluid. Therefore, novel treatment strategies,
including the possibility of therapeutic drug
monitoring within serum and cerebrospinal fluid,
should be investigated in further clinical studies.
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